What is AMF Pharma?
AMF Pharma operates as a fully licensed cGMP contract manufacturer and private label specialist, dedicated to the production of dietary supplements. The company distinguishes itself through a commitment to rigorous quality control standards and competitive pricing models, catering to a diverse client base that requires high-volume production capabilities. With a capacity to handle substantial orders—often reaching 300,000 tablets or capsules—the firm serves as a critical link in the health and wellness supply chain. Its business model is built upon the pillars of integrity, technical knowledge, and operational efficiency, ensuring that clients receive superior products within a reliable 4-8 week lead time, subject to specific product complexities.
How much funding has AMF Pharma raised?
AMF Pharma has raised a total of $318K across 2 funding rounds:
Debt
$150K
Debt
$168K
Debt (2020): $150K with participation from PPP
Debt (2021): $168K led by PPP
Key Investors in AMF Pharma
PPP
Public-Private Partnership
What's next for AMF Pharma?
With the recent influx of capital, AMF Pharma is well-positioned to optimize its manufacturing infrastructure and expand its market reach. The strategic focus will likely shift toward enhancing production throughput and diversifying its service offerings to meet the evolving demands of the global supplement market. By maintaining its cGMP compliance and investing in advanced manufacturing technologies, the company aims to further reduce lead times and increase its competitive advantage. This late-stage financial support provides the necessary liquidity to scale operations, potentially exploring new product categories or increasing capacity to accommodate larger enterprise-level partnerships, thereby cementing its status as a leader in the contract manufacturing sector.
See full AMF Pharma company page
